These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30076413)

  • 1. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
    Tessari A; Parbhoo K; Pawlikowski M; Fassan M; Rulli E; Foray C; Fabbri A; Embrione V; Ganzinelli M; Capece M; Campbell MJ; Broggini M; La Perle K; Farina G; Cole S; Marabese M; Hernandez M; Amann JM; Pruneri G; Carbone DP; Garassino MC; Croce CM; Palmieri D; Coppola V
    Oncogene; 2018 Dec; 37(50):6463-6476. PubMed ID: 30076413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scorpins in the DNA Damage Response.
    Palmieri D; Tessari A; Coppola V
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29914204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KIAA1522 potentiates TNFα-NFκB signaling to antagonize platinum-based chemotherapy in lung adenocarcinoma.
    Wang B; Jing T; Jin W; Chen J; Wu C; Wang M; Liu Y
    J Exp Clin Cancer Res; 2020 Aug; 39(1):170. PubMed ID: 32854746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ran Binding Protein 9 (RanBP9) is a novel mediator of cellular DNA damage response in lung cancer cells.
    Palmieri D; Scarpa M; Tessari A; Uka R; Amari F; Lee C; Richmond T; Foray C; Sheetz T; Braddom A; Burd CE; Parvin JD; Ludwig T; Croce CM; Coppola V
    Oncotarget; 2016 Apr; 7(14):18371-83. PubMed ID: 26943034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.
    Bell EH; Chakraborty AR; Mo X; Liu Z; Shilo K; Kirste S; Stegmaier P; McNulty M; Karachaliou N; Rosell R; Bepler G; Carbone DP; Chakravarti A
    Clin Cancer Res; 2016 May; 22(10):2396-404. PubMed ID: 26671993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
    Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
    Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of RIF1 on response of non-small-cell lung cancer patients to platinum-based chemotherapy by regulating MYC signaling pathway.
    Mei Y; Liu YB; Hu DL; Zhou HH
    Int J Biol Sci; 2018; 14(13):1859-1872. PubMed ID: 30443189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RANBP9 as potential therapeutic target in non-small cell lung cancer.
    Tessari A; Soliman SHA; Orlacchio A; Capece M; Amann JM; Visone R; Carbone DP; Palmieri D; Coppola V
    J Cancer Metastasis Treat; 2020; 6():. PubMed ID: 34778565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1.
    Zhang H; Hu B; Wang Z; Zhang F; Wei H; Li L
    Cancer Chemother Pharmacol; 2017 Nov; 80(5):973-984. PubMed ID: 28956120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ARRB1 enhances the chemosensitivity of lung cancer through the mediation of DNA damage response.
    Shen H; Wang L; Zhang J; Dong W; Zhang T; Ni Y; Cao H; Wang K; Li Y; Wang Y; Du J
    Oncol Rep; 2017 Feb; 37(2):761-767. PubMed ID: 28035404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recruitment of KMT2C/MLL3 to DNA Damage Sites Mediates DNA Damage Responses and Regulates PARP Inhibitor Sensitivity in Cancer.
    Chang A; Liu L; Ashby JM; Wu D; Chen Y; O'Neill SS; Huang S; Wang J; Wang G; Cheng D; Tan X; Petty WJ; Pasche BC; Xiang R; Zhang W; Sun P
    Cancer Res; 2021 Jun; 81(12):3358-3373. PubMed ID: 33853832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-495 enhances the sensitivity of non-small cell lung cancer cells to platinum by modulation of copper-transporting P-type adenosine triphosphatase A (ATP7A).
    Song L; Li Y; Li W; Wu S; Li Z
    J Cell Biochem; 2014 Jul; 115(7):1234-42. PubMed ID: 24038379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibition induces BAX/BAK-independent synthetic lethality of BRCA1-deficient non-small cell lung cancer.
    Paul I; Savage KI; Blayney JK; Lamers E; Gately K; Kerr K; Sheaff M; Arthur K; Richard DJ; Hamilton PW; James JA; O'Byrne KJ; Harkin DP; Quinn JE; Fennell DA
    J Pathol; 2011 Aug; 224(4):564-74. PubMed ID: 21706479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenomic profiling of non-small cell lung cancer xenografts uncover LRP12 DNA methylation as predictive biomarker for carboplatin resistance.
    Grasse S; Lienhard M; Frese S; Kerick M; Steinbach A; Grimm C; Hussong M; Rolff J; Becker M; Dreher F; Schirmer U; Boerno S; Ramisch A; Leschber G; Timmermann B; Grohé C; Lüders H; Vingron M; Fichtner I; Klein S; Odenthal M; Büttner R; Lehrach H; Sültmann H; Herwig R; Schweiger MR
    Genome Med; 2018 Jul; 10(1):55. PubMed ID: 30029672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.